When Alex Nemiroff’s son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.
Natural History Studies (NHS) are important in planning trials of treatment. We talk with Dr Katherine Howell, principal investigator of the SCN2A NHS.
Prof Ingrid Scheffer has published many key papers in SCN2A and genetic epilepsies and discusses the progress that has been made in understanding SCN2A.
Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders.
The following work from Assistant Prof. Kevin Benders lab was presented on the 20th of October in Chicago, at Neuroscience 2019 held by Society for
The SCN2A International Natural History Study (NHS) is comprised of clinicians collaborating from multiple academic institutions, including US, European and Australian based clinicians. Dr. Katherine
Today we are introducing the SCN2A research team at the Florey Institute. The team is lead by Prof Steven Petrou, Director of Florey Institute. The
Happy Australia Day! Today we launch SCN2A Australia. We look forward to working with families, researchers, clinicians and professional bodies to improve the lives of
© All rights reserved. SCN2A Australia | Privacy Policy
